Table 2 Multivariable analysis with OS and EFS in the primary cohort of 179 AML patients (TCGA dataset)
Variables in final model by end point | HR | 95% CI | P value |
|---|---|---|---|
OS (all AML, n = 179) | |||
ETS2 expression, high vs. low | 1.79 | 1.23–2.59 | 0.002 |
Age, per 10-year increase | 1.46 | 1.27–1.68 | <0.001 |
CEBPA mutation vs. wild | 1.75 | 0.85–3.58 | 0.13 |
NPM1 mutation vs. wild | 1.1 | 0.73–1.66 | 0.65 |
FLT3-ITD, presented vs. others | 1.24 | 0.78–1.96 | 0.37 |
EFS (all AML, n = 179) | |||
ETS2 expression, high vs. low | 1.88 | 1.32–2.68 | <0.001 |
Age, per 10-year increase | 1.34 | 1.18–1.53 | <0.001 |
CEBPA mutation vs. wild | 1.2 | 0.92–3.57 | 0.08 |
NPM1 mutation vs. wild | 1.2 | 0.83–1.78 | 0.3 |
FLT3-ITD, presented vs. others | 1.4 | 0.9–2.15 | 0.1 |
RFS (all AML, n = 177) | |||
ETS2 expression, high vs. low | 2.23 | 1.41–3.5 | <0.001 |
Age, per 10-year increase | 1.13 | 0.96–1.33 | 0.14 |
CEBPA mutation vs. wild | 0.4 | 0.94–4.48 | 0.07 |
NPM1 mutation vs. wild | 0.25 | 0.81–2.15 | 0.26 |
FLT3-ITD, presented vs. others | 1.47 | 0.86–2.53 | 0.16 |